The earnings call highlighted significant progress in clinical trials and global expansion efforts, supported by a strong financial position and promising market research. However, challenges remain in sales consistency and the brief commercial history in the WHIM market.

Company Guidance

During the X4 Pharmaceuticals Q1 2025 financial call, the company provided several key metrics and updates. The 4WARD trial, a pivotal Phase III study for mavorixafor in chronic neutropenia (CN), is actively enrolling participants with over 90% of global trial sites activated. The trial aims to demonstrate statistically significant improvements in absolute neutrophil count (ANC) response and reductions in annualized infection rates, targeting a CN population of about 15,000 in the US with high unmet medical needs. The trial is powered at over 95% for the ANC endpoint and over 90% for infection rate outcomes. X4 anticipates full enrollment by Q3 or Q4 2025, with top-line data expected in H2 2026. Financially, X4 reported ending Q1 with just under $90 million in cash, with cumulative XOLREMDI sales reaching $3.5 million since its May 2024 launch. Additionally, the company highlighted its strategic partnerships for expanding mavorixafor's reach globally, including expected EMA approval by Q1 2026.

Clinical Trial Advancements

X4 advanced the 4WARD Phase III trial for chronic neutropenia (CN), with over 90% of global trial sites activated and a finalized trial design based on regulatory feedback.

US Patent Allowance

Received a notice of allowance from the US patent office for using mavorixafor to treat severe chronic idiopathic and autoimmune neutropenia, with an expiration date in March 2041.

Global Expansion Efforts

Mavorixafor's MAA was accepted by European authorities, with potential EMA approval expected by Q1 2026. New partnerships established for commercialization in Europe, Australia, New Zealand, and the MENA region.

Financial Position

Ended Q1 2025 with nearly $90 million in cash and equivalents, with sufficient funds to support operations into the first half of 2026.

Positive Market Research for CN

Completed a survey with 95 US physicians, revealing higher case loads and a clear unmet need in the CN market.

X4 Pharmaceuticals (XFOR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XFOR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	- / -	-5.4	―	―	―
Jul 31, 2025	2025 (Q2)	-3.37 / -3.47	13.5	-125.72% (-16.97)	―	―
May 01, 2025	2025 (Q1)	-3.55 / 0.04	-7.8	100.51% (+7.84)
Mar 25, 2025	2024 (Q4)	-5.28 / -6.00	-3	-100.00% (-3.00)	―
Nov 13, 2024	2024 (Q3)	-5.14 / -5.40	-0.3	-1700.00% (-5.10)
Aug 08, 2024	2024 (Q2)	-0.21 / 13.50	-9.9	236.36% (+23.40)	―
May 07, 2024	2024 (Q1)	-4.63 / -7.80	-4.8	-62.50% (-3.00)	―
Mar 21, 2024	2023 (Q4)	-4.37 / -3.00	-8.7	65.52% (+5.70)	―
Nov 09, 2023	2023 (Q3)	-4.47 / -0.30	-7.8	96.15% (+7.50)
Aug 10, 2023	2023 (Q2)	-4.87 / -9.90	-18	45.00% (+8.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XFOR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$1.77	$1.68	-5.08%
May 01, 2025	$4.31	$3.75	-12.99%
Mar 25, 2025	$8.85	$7.78	-12.09%
Nov 13, 2024	$17.76	$8.32	-53.15%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does X4 Pharmaceuticals Inc (XFOR) report earnings?

X4 Pharmaceuticals Inc (XFOR) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is X4 Pharmaceuticals Inc (XFOR) earnings time?

X4 Pharmaceuticals Inc (XFOR) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XFOR EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing